A Review on the Neurotoxic Effects of Doxorubicin.
Katarzyna KamińskaAgnieszka Cudnoch-JedrzejewskaPublished in: Neurotoxicity research (2023)
Anthracyclines, a class of drugs considered as most effective anticancer drugs, used in the various regimens of cancer chemotherapy, induce long-term impairment of mitochondrial respiration, increase reactive oxygen species, and induce other mechanisms potentially leading to neurotoxicity. According to literature findings, one drug of this class - doxorubicin used to treat e.g. breast cancer, bladder cancer, lymphoma, and acute lymphocytic leukemia may induce such effects in the nervous system. Doxorubicin has poor penetration into the brain due to the lack of drug penetration through the blood-brain barrier, thus the toxicity of this agent is the result of its peripheral action. This action is manifested by cognitive impairment and anatomical changes in the brain and peripheral nervous system found in both preclinical and clinical studies in adult patients. Furthermore, more than 50% of children with cancer are treated with anthracyclines including doxorubicin, which may affect their nervous system, and lead to lifelong damage in many areas of their life. Despite ongoing research into the side effects of this drug, the mechanism of its neurotoxicity action on the central and peripheral nervous system is still not well understood. This review aims to summarize the neurotoxic effects of doxorubicin in preclinical (in vitro and in vivo) research and in clinical studies. Furthermore, it discusses the possible mechanisms of the toxic action of this agent on the nervous system.
Keyphrases
- drug delivery
- cancer therapy
- papillary thyroid
- drug induced
- cognitive impairment
- oxidative stress
- reactive oxygen species
- chemotherapy induced
- systematic review
- white matter
- resting state
- squamous cell
- acute myeloid leukemia
- liver failure
- stem cells
- cell therapy
- squamous cell carcinoma
- lymph node metastasis
- cerebral ischemia
- functional connectivity
- diffuse large b cell lymphoma
- intensive care unit
- hepatitis b virus
- radiation therapy